GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone240-243-1201
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20,000.00
Profitability
Miscellaneous
Employees40
OptionableOptionable
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) posted its quarterly earnings data on Friday, November, 2nd. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.03. View GlycoMimetics' Earnings History.
When is GlycoMimetics' next earnings date?
What price target have analysts set for GLYC?
4 equities research analysts have issued 12-month target prices for GlycoMimetics' shares. Their predictions range from $24.00 to $35.00. On average, they anticipate GlycoMimetics' stock price to reach $27.6667 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View Analyst Price Targets for GlycoMimetics.
What is the consensus analysts' recommendation for GlycoMimetics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.
Has GlycoMimetics been receiving favorable news coverage?
News articles about GLYC stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. GlycoMimetics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Myokardia (MYOK), Allakos (ALLK), Insmed (INSM), Corcept Therapeutics (CORT), Zogenix (ZGNX), PTC Therapeutics (PTCT), Madrigal Pharmaceuticals (MDGL), Portola Pharmaceuticals (PTLA), Mallinckrodt (MNK), Vanda Pharmaceuticals (VNDA), Pacira Pharmaceuticals (PCRX), Zai Lab (ZLAB), Prestige Consumer Healthcare (PBH), Theravance Biopharma (TBPH) and The Medicines (MDCO).
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Ms. Rachel K. King, Pres, CEO & Director (Age 60)
- Mr. Brian M. Hahn, CFO & Sec. (Age 45)
- Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
- Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
- Mr. Henry Flanner, VP of Technical Operations
Who are GlycoMimetics' major shareholders?
GlycoMimetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Prentiss Smith & Co. Inc. (0.02%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Helen M Thackray, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.
Which major investors are buying GlycoMimetics stock?
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $10.95.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $461.14 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.
What is GlycoMimetics' official website?
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
